• Publications
  • Influence
The natural history of benign prostatic hyperplasia.
Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancer: Relation to Antiandrogen Withdrawal Syndrome
The results indicate that a codon 877 mutation in the AR gene in advanced prostate cancer evokes the antiandrogen withdrawal syndrome and that the mutation is found in relation to endocrine therapy resistance. Expand
Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both
Radical prostatectomy combined with endocrine therapy may contribute to the survival benefit of patients with locally advanced prostate cancer and can be used in selected patients because of its low morbidity. Expand
Mesenteric Castleman tumor.
Computed tomography in a case of mesenteric Castleman tumor showed a well-circumscribed homogeneous soft tissue density mass with moderate contrast enhancement after injection of contrast material.Expand
Prognosis of Patients with Prostate Carcinoma Presenting as Nonregional Lymph Node Metastases
Endocrine therapy was effective even in patients with distant lymph node metastases, and patients without bone metastases at the initial diagnosis could survive longer than those with metastases to bone. Expand
Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates
Androgen receptor was detected immunohistochemically in benign as well as malignant prostatic tissues by using a monoclonal rat anti‐human androgen receptor antibody (AN 1–15). In both benign andExpand
Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma
The ratio of androgen receptor‐containing cells in cancerous tissues was determined by immunohistochemical staining of prostate biopsy specimens for comparison with the outcome. Expand
Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.
Withdrawal of the steroidal antiandrogen CMA resulted in a decline in PSA levels and clinical improvement in prostate cancer patients with disease progression, and changes in testosterone, prolactin, or adrenal androgens were not a cause of the anti androgen withdrawal syndrome. Expand
State of Adenomatous Polyposis Coli Gene and ras Oncogenes in Japanese Prostate Cancer
The results indicate that ras oncogene mutations are related to the progression of prostate cancer, whereas APC gene alteration is not involved in tumorigenesis and development of this cancer. Expand
Radiotherapy for local progression in patients with hormone‐refractory prostate cancer
The aim of the present study was to investigate the effect of radiotherapy on the local progression of hormone‐refractory prostate cancer and the role radiotherapy played in this progression. Expand